In vitro and in vivo synergistic efficacy of ceritinib combined with programmed cell death ligand‐1 inhibitor in anaplastic lymphoma kinase‐rearranged non‐small‐cell lung cancer

Both ceritinib (CER) and programmed cell death (PD)‐1/PD ligand‐1 (PD‐L1) have brought significant breakthroughs for anaplastic lymphoma kinase (ALK)‐rearranged non‐small‐cell lung cancer (NSCLC). However, the overall clinical efficacy of either CER or PD‐1/PD‐L1 inhibitor monotherapy has been limit...

Descripción completa

Detalles Bibliográficos
Autores principales: Du, Ping, Hu, Ting, An, Zhuoling, Li, Pengfei, Liu, Lihong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7293083/
https://www.ncbi.nlm.nih.gov/pubmed/32227409
http://dx.doi.org/10.1111/cas.14397

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7293083/
https://www.ncbi.nlm.nih.gov/pubmed/32227409
http://dx.doi.org/10.1111/cas.14397

Ejemplares similares